Management of Ectopic Pregnancy by Intramuscular Injection of High Dose of Methotrexate

徐宣枝,余奇侠,曾菲,左绪磊

DOI: https://doi.org/10.3760/cma.j.issn.1008-1372.2003.07.021

2003-01-01

Abstract:Objective To explore the optimal indication and safety of managing ectopic pregnancy by intramuscular injection of high dose of methotrexate.Methods The patient with unruptured ectopic pregnancy was injected with 50mg/m 2 of methotrexate, the injection of methotrexate was repeated at the same dose if the level of the β-subunit of human chorionic gonadotropin continues to rise or maintain at a high level 7 days after the primary injection.Results Of 109 cases,100 the patients with ectopic pregnancy were succeeded by conservative therapy. The total success rate was 91 7%. The success rate was 97 7% in patients with a level of the β-subunit of human chorionic gonadotropin less than 2 5 nmol/L (the normal value is less than 0 82nmol/L), whereas it was 66 7% in patients with a level of the β-subunit of human chorionic gonadotropin greater than 2 5nmol/L, the difference was statistically significant (P0 001). And 2 3% of cases in the former group needed a repeated injection at the same dose, and there was as high as 50% of patients in the latter group received repeated injection. The difference between two groups was significant as well (P0 001). In addition, 2 cases of patients with a mild neutropenia were discovered, and 1 case of ovarian carcinoma was one and half year followed by the medicament therapy of the ectopic pregnancy.There were 2 patients in intraperitoneal bleeding after discharge from the hospital.Conclusions It is effective in managing patients with ectopic pregnancy by using high dosage intramuscular injection of methotrexate at the early stage. In especial the patients with a level of β-subunit of human chorionic gonadotropin less than 2 5nmol/L is optimal therapy.It should not consider the chemotherapeutic management in patients with a β-subunit of human chorionic gonadotropin greater than 2 5nmol/L,with a familial history of cancer, and with a disposition to malignant status.